Nuvalent, Inc.
NUVLDelisted Jul 15, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001861560
Nuvalent, Inc. was delisted on Jul 15, 2026; its insiders filed their last Form 4 on Jul 17, 2026; 292 institutions reported holding it in 13F filings for Q2 2026, worth $9.29B in total; Soros Fund Management was the only superinvestor holding it.
13F holders, Q3 2023
Institutional positions in Nuvalent, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 116
- +5 vs. Q2 2023
- Shares held
- 55.8M
- +570.8K (+1.0%) vs. Q2 2023
- Total value
- $2.57B
- +$236.4M (+10.1%) vs. Q2 2023
- New holders
- 15
- 56 more added
- Sold out
- 10
- 31 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NUVL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 292 | $9.29B |
| Q1 2026 | 265 | $8.30B |
| Q4 2025 | 237 | $8.04B |
| Q3 2025 | 196 | $6.26B |
| Q2 2025 | 209 | $5.49B |
| Q1 2025 | 205 | $5.11B |
| Q4 2024 | 217 | $5.53B |
| Q3 2024 | 193 | $7.17B |
| Q2 2024 | 172 | $4.98B |
| Q1 2024 | 180 | $4.78B |
| Q4 2023 | 155 | $4.68B |
| Q3 2023 | 116 | $2.57B |
| Q2 2023 | 111 | $2.33B |
| Q1 2023 | 89 | $1.41B |
| Q4 2022 | 96 | $1.58B |
| Q3 2022 | 60 | $879.5M |
| Q2 2022 | 55 | $622.5M |
| Q1 2022 | 55 | $629.0M |
| Q4 2021 | 49 | $813.1M |
| Q3 2021 | 47 | $941.2M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Nuvalent, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 545,349 | $25.1M | 0.00% | +16,858+3.2% | Added |
| Price T Rowe Associates Inc | 806,936 | $37.1M | 0.01% | +231,258+40.2% | Added |
| Avoro Capital Advisors LLC | 812,500 | $37.4M | 0.58% | −787,500−49.2% | Reduced |
| Commodore Capital LP | 828,778 | $38.1M | 4.45% | −321,222−27.9% | Reduced |
| Boxer Capital, LLC | 1,210,192 | $55.6M | 2.96% | 00.0% | Unchanged |
| Driehaus Capital Management LLC | 1,239,403 | $57.0M | 0.74% | −201,327−14.0% | Reduced |
| State Street Corp | 1,260,466 | $57.9M | 0.00% | +92,477+7.9% | Added |
| Wellington Management Group LLP | 1,556,367 | $71.5M | 0.01% | −180,120−10.4% | Reduced |
| Paradigm Biocapital Advisors LP | 1,638,147 | $75.3M | 5.14% | +517,682+46.2% | Added |
| Vanguard Group Inc | 2,134,182 | $98.1M | 0.00% | +15,722+0.7% | Added |
| BlackRock Inc. | 2,429,979 | $111.7M | 0.00% | +33,115+1.4% | Added |
| Fairmount Funds Management LLC | 2,451,819 | $112.7M | 13.56% | −432,673−15.0% | Reduced |
| Perceptive Advisors LLC | 2,463,451 | $113.2M | 3.81% | +268,630+12.2% | Added |
| Bain Capital Life Sciences Investors, LLC | 3,577,267 | $164.4M | 18.39% | 00.0% | Unchanged |
| FMR LLC | 7,619,613 | $350.3M | 0.03% | +1,4890.0% | Added |
| Deerfield Management Company, L.P. (Series C) | 19,991,024 | $919.0M | 20.25% | 00.0% | Unchanged |
| Silverarc Capital Management, LLC | 0 | $0 | 0.00% | −115,067−100.0% | Sold out |
| Great Lakes Advisors, LLC | 0 | $0 | 0.00% | −103,712−100.0% | Sold out |
| Prudential Financial Inc | 0 | $0 | 0.00% | −15,935−100.0% | Sold out |
| Jefferies Financial Group Inc. | 0 | $0 | 0.00% | −14,600−100.0% | Sold out |
| Meitav Dash Investments Ltd | 0 | $0 | 0.00% | −7,000−100.0% | Sold out |
| Verition Fund Management LLC | 0 | $0 | 0.00% | −7,850−100.0% | Sold out |
| Connor, Clark & Lunn Investment Management Ltd. | 0 | $0 | 0.00% | −7,815−100.0% | Sold out |
| Atom Investors LP | 0 | $0 | 0.00% | −5,104−100.0% | Sold out |
| SEI Investments Co | 0 | $0 | 0.00% | −4,949−100.0% | Sold out |
| Carolinas Wealth Consulting LLC | 0 | $0 | 0.00% | −10−100.0% | Sold out |